NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, an established leader in the development of innovative, proven, and trusted weight loss experiences, today announced the Premarket Approval (PMA) ...
At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable safety ...
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical ...
The U.S. Food and Drug Administration has approved “the world’s first and only swallowable" gastric balloon for weight loss that requires no surgery, anesthesia or other procedures, Allurion ...
Planning for major weight loss may soon become an easier pill − or balloon − to swallow. As manufacturers ramp up for a GLP-1 legal battle and every food brand seems to be releasing new protein-packed ...
In the AUDACITY trial, 58% of patients using the Allurion Balloon achieved at least a 5% total body weight loss at 48 weeks. The Food and Drug Administration (FDA) has approved Allurion Gastric ...
Findings from two abstracts presented at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting reinforce the role of the AI-powered Allurion Program in delivering ...
In 522 patients, average weight loss was approximately 32 pounds at balloon passage and 31 pounds 1 year later, equating to approximately 95% weight maintenance In 497 patients, average weight loss ...
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results